Ethical and economic considerations of rare diseases in ethnic minorities: the case of mucopolysaccharidosis VI in Colombia
Share this article
Click the icon of the social media platform on which you would like to share this article.
Email this article to a friend
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Other content recommended for you
- Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis
- Cardiac issues in adults with the mucopolysaccharidoses: current knowledge and emerging needs
- Progression of eye disease over 15 years in a patient with mucopolysaccharidosis type VI on enzyme replacement therapy
- Screening patients referred to a metabolic clinic for lysosomal storage disorders
- Musculoskeletal manifestations of lysosomal storage disorders
- Bio-Plex immunoassay measuring the quantity of lysosomal N-acetylgalactosamine-6-sulfatase protein in dried blood spots for the screening of mucopolysaccharidosis IVA in newborn: a pilot study
- ‘Doctor Google’ ending the diagnostic odyssey in lysosomal storage disorders: parents using internet search engines as an efficient diagnostic strategy in rare diseases
- Clinical and morphological features including expression of βig-h3 and keratan sulphate proteoglycans in Maroteaux-Lamy syndrome type B and in normal cornea
- Clinical course of sly syndrome (mucopolysaccharidosis type VII)
- Avoiding diagnostic delay for mucopolysaccharidosis IIIB: do not overlook common clues such as wheezing and otitis media